This work is licensed under a Creative Commons Attribution 4.0 International License.
P2shortA
General Information
DCTPep ID DCTPep05919
Peptide Name P2shortA
Sequence ALPISTVRⓍVALⓍRRL
Sequence Length 16
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
ACP Tumor active peptide Cancer targeted peptides Stapled Peptides Induce apoptosis Induce cell cycle arrest MDM6/MDMX Inhibitor
Activity Information
| Cell Line | Disease | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|
| A549 | Lung adenocarcinoma | 50% Killing=10 μM | Crystal violet dye | 24, 48 or 72 h | 1 |
| PC-9 | Lung adenocarcinoma | 80% Killing=10 μM | Crystal violet dye | 24, 48 or 72 h | 1 |
| NCI-H358 | Minimally invasive lung adenocarcinoma | 98% Killing=10 μM | Crystal violet dye | 24, 48 or 72 h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure Not available
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity 74
Linear/Cyclic Cyclic (Stapled)
Disulfide/Other Bond Stapled: Ⓧ(9) and Ⓧ (13) are cross-linked by hydrocarbon stapling
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification Ⓧ=(S)-pentenylalanine
Chiral L
Physicochemical Information
Formula Not Applicable
Absent amino acids Not Applicable
Theoretical pI Not Applicable
Acidic residues Not Applicable
Basic residues Not Applicable
Polar residues Not Applicable
Molecular weight (Average) Not Applicable
Molecular weight (Monoisotopic) Not Applicable
Common amino acids Not Applicable
Net charge Not Applicable
Instability index (II) Not Applicable
Aliphatic index Not Applicable
Grand average of hydropathicity (GRAVY) Not Applicable
Half Life
Not Applicable
Extinction coefficients
Not Applicable
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 32104498
Title Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth
Year 2020
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.